News

Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds

Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Results from the so-called AFF008 study program were recently presented at the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD) in…

Affected Cell Type May Explain Differences in Parkinson’s-related Diseases, Study Suggests

Different brain cells determine which form of alpha-synuclein will be responsible for different Parkinson’s-related disorders, a new study suggests. The research, “Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies,” was published in the journal Nature. Aggregates of the protein alpha-synuclein are characteristic of Parkinson’s, Lewy body…

MJFF Partners with Verily to Use Data Collection Watch in PPMI Study to Advance Parkinson’s Research

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Verily Life Sciences are collaborating to collect data on movement, physiological, and environmental measures in Parkinson’s patients for the MJFF-led Parkinson’s Progression Markers Initiative (PPMI). More than 800 PPMI participants will be outfitted with Verily’s investigational Study Watch, a multi-sensor…